New Zealand markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.2800-0.0700 (-2.98%)
At close: 03:59PM EDT
2.4300 +0.15 (+6.58%)
After hours: 06:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3500
Open2.3148
Bid0.0000 x 1300
Ask0.0000 x 800
Day's range2.2000 - 2.3200
52-week range1.6400 - 3.3300
Volume11,672
Avg. volume20,709
Market cap13.976M
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-1.4800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • Business Wire

    Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

    RAMAT GAN, Israel, April 03, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s on

  • Business Wire

    Can-Fite Reports 2023 Financial Results and Clinical Update

    RAMAT GAN, Israel, March 28, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.

  • Business Wire

    Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

    PETACH TIKVA, Israel, March 11, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024 (https://informaconnect.com/bioeurop